Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released...
Finanical Reports
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released...
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues...
Jiangsu Hengrui Pharmaceuticals Reports 7.26% Revenue Growth in 2023, Driven by Innovative Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has released...
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for...
CSPC Pharmaceutical Posts 1.7% Revenue Growth in 2023, Bolstered by Patent Medicine Sales
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has released...
Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023
Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...
J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact
Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...
Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...
Shanghai Junshi Biosciences Reports 3.38% YOY Revenue Growth in 2023 Financials
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China,...
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report...
Alphamab Oncology Reports 31.12% Revenue Growth in 2023 with Continued R&D Focus
Alphamab Oncology (HKG: 9966), a Chinese biopharmaceutical company, has released its financial performance and business...
Bio-Thera Solutions Reports 54.86% YOY Revenue Growth in 2023, Led by Biosimilar Sales
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company headquartered in Guangzhou, has announced its financial results...
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with...
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge...
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023...
Everest Medicines Reports 884% Revenue Surge Amid Rising Losses and Strategic Shifts
Everest Medicines (HKG: 1952), a China-based biotech company, has released its 2023 annual financial results...
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...